Diabetics on Januvia, Byetta at Double the Risk for Pancreatitis

Researchers at Johns Hopkins have found that diabetes who take the medications Januvia and Byetta are at a significantly elevated risk of developing dangerous pancreatic inflammation. Januvia and Byetta are glucagon-like peptide-1 based drugs.

The researchers found that people taking these drugs are twice as likely as other diabetics to be hospitalized with pancreatitis within 60 days of starting the drug. They recommend that care providers be alert to the symptoms of pancreatitis, including abdominal pain, nausea and persistent vomiting.

To learn more, click here.